Atlas Trials

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Clinical trial NCT06647329 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06647329
Sponsor
Mingzhi Zhang
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
CAR-T Cell TherapyLymphomas
Start date
2024-12-01
Primary completion
2025-12-31
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.